Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Posard Matthew L.
Apr 29 18:14 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Miyashita Akiko Moni
Apr 29 18:10 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director MATSUI CONNIE
Apr 29 18:09 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krishnan Mahesh
Apr 29 18:04 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Henderson Jeffrey William
Apr 29 17:59 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Duncan Barbara Gayle
Apr 29 17:59 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Connaughton Bernadette
Apr 29 17:54 ET
Halozyme Therapeutics | 8-K: Current report
Apr 26 16:26 ET
Halozyme Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Krishnan Mahesh
Apr 25 16:17 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer LaBarre Michael J.
Apr 17 19:25 ET
Halozyme Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Apr 17 16:05 ET
Halozyme Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Apr 16 16:07 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer LaBarre Michael J.
Mar 26 19:40 ET
Halozyme Therapeutics | ARS: Annual Report to Security Holders
Mar 15 16:56 ET
Halozyme Therapeutics | DEFA14A: Others
Mar 15 16:24 ET
Halozyme Therapeutics | DEF 14A: Definitive information statements
Mar 15 16:14 ET
Halozyme Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer LaBarre Michael J.
Mar 13 17:26 ET
Halozyme Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 13 16:20 ET
Halozyme Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 12 16:14 ET
Halozyme Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Mar 4 16:17 ET
No Data
No Data